Hepion Pharmaceuticals Inc (HEPA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access HEPA Annual Balance Sheets →
Reviewing balance sheet figures over time helps illustrate how Hepion Pharmaceuticals Inc manages its resources, obligations, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent1.63
Cash & Short-term Investments1.00
Prepaid Expense, Current AS0.30
Total Current Assets1.93
Other Assets, Noncurrent0.00
Total Assets1.93
Liabilities
Accounts Payable, Current AC0.17
Accrued Liabilities, Current AC0.32
Notes Payable, Current NO0.00
Other Liabilities, Current0.00
Taxes Payable0.13
Total Current Liabilities0.49
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE0.16
Total Liabilities0.65
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock247.73
Retained Earnings / Accumulated Deficit-248.16
Accumulated Other Comprehensive Income0.01
Other Equity0.01
Common Stockholder's Equity1.28
Preferred Stockholder's Equity0.00
Total Stockholder's Equity1.28
Liabilities & Stockholder's Equity1.93
4 historic quarters locked

Sign in to unlock the full Hepion Pharmaceuticals Inc balance sheet history.

About Hepion Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-037562

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.